



Advances in Prognosis and Theranostics of Cancer

Guest Editors:

Dr. Sudip Mukherjee

Department of Bioengineering,
Rice University, 6500 Main Street,
Houston, TX 77005, USA

Dr. Manash Paul

Division of Pulmonary and
Critical Care Medicine, David
Geffen School of Medicine, The
University of California, Los
Angeles (UCLA), Los Angeles, CA
90095, USA.

Deadline for manuscript
submissions:

closed (31 December 2021)

Message from the Guest Editors

Dear Colleagues,

Cancer is one of the leading causes of death worldwide. As per the recent cancer statistics data, cancer accounts for an estimated 18.1 million cancer cases and 9.5 million deaths in 2018. Although advances have been made in the treatment of cancers, there are still many existing challenges mainly due to the lack of an early diagnosis and inefficiency in conventional therapies, which causes poor prognosis and overall survival of cancer patients.

Hence alternative prognostic, therapeutic, and diagnostic approaches are required to reduce overall mortality and improve patient quality of life. In this present issue, we will publish research, reviews, and short communications on the modern approaches to combat cancer. Contributions on biomarker discovery, diagnosis, therapeutic modalities including immunotherapy, cancer vaccines, biomaterials-based theranostics approaches, nanomedicine-based theranostics, small molecule-based targeting, immunomodulatory approaches and other emergent approaches in precision oncology are also encouraged.

Dr. Sudip Mukherjee

Dr. Manash Paul

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)